外科理论与实践

外科理论与实践 >

2022 , Vol. 27 >Issue 05: 473 - 477

DOI: https://doi.org/10.16139/j.1007-9610.2022.05.018

综述

Trop2基因与三阴性乳腺癌的研究进展

展开
  • 广东医科大学第一临床医学院，广东 湛江 524000

收稿日期: 2021-04-27

  网络出版日期: 2022-11-10

收起

Study on trophoblast cell-surface antigen 2 gene and triple-negative breast cancer

Expand
  • Breast Center, Zhaoqing First People′s Hospital affiliated to Guangdong Medical University, Guangdong Zhanjiang 524000, China

Received date: 2021-04-27

  Online published: 2022-11-10

Fold

摘要

Trop2基因在多种恶性肿瘤的发生、发展中起重要作用。三阴性乳腺癌（triple-negative breast cancer, TNBC）的滋养层细胞表面抗原2（trophoblast cell-surface antigen 2, Trop2）基因能调控周期蛋白D1（cyclin D1）及上皮钙黏素的表达，进而促进TNBC转移及侵袭。本文对Trop2基因的结构、功能、作用机制及在TNBC中的表达和治疗进行综述，以期找到TNBC的治疗靶点，探索新疗法。

关键词： 三阴性乳腺癌; Trop2基因; 靶向治疗

本文引用格式

王杰强 综述, 马德奎 审校 . Trop2基因与三阴性乳腺癌的研究进展[J]. 外科理论与实践, 2022 , 27(05) : 473 -477 . DOI: 10.16139/j.1007-9610.2022.05.018

Abstract

Trophoblast cell-surface antigen 2(Trop2) gene plays an important role in the development of various malignant tumors. Trop2 gene regulates the expression of cyclin D1 and E-cadherin in triple-negative breast cancer (TNBC), and promote the metastasis and invasion of TNBC. In this study, the structure, function, mechanism of action, the expression of Trop2 gene and treatment of TNBC were reviewed to find therapeutic targets for TNBC and explore new therapy.

Key words： Triple-negative breast cancer; Trop2 gene; Targeted therapy

参考文献

[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
[2] Kumar P, Aggarwal R. An overview of triple-negative breast cancer[J]. Arch Gynecol Obstet, 2016, 293(2):247-269.
[3] Sharma P. Biology and management of patients with triple-negative breast cancer[J]. Oncologist, 2016, 21(9):1050-1062.
[4] McDougall AR, Tolcos M, Hooper SB, et al. Trop2: from development to disease[J]. Dev Dyn, 2015, 244(2):99-109.
[5] Cubas R, Zhang S, Li M, et al. Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway[J]. Mol Cancer, 2010, 9:253.
[6] 张喆, 贾立周, 唐奇, 等. TROP2和VEGFR2在三阴性乳腺癌中的表达及与临床病理因素的相关性研究[J]. 南京医科大学学报(自然科学版), 2019, 39(10):1453-1458.
[7] Li X, Teng S, Zhang Y, et al. TROP2 promotes prolife-ration, migration and metastasis of gallbladder cancer cells by regulating PI3K/AKT pathway and inducing EMT[J]. Oncotarget, 2017, 8(29):47052-47063.
[8] Vidmar T, Pavšiŏc M, Lenarŏciŏc B. Biochemical and preliminary X-ray characterization of the tumor-associated calcium signal transducer 2 (Trop2) ectodomain[J]. Protein Expr Purif, 2013, 91(1):69-76.
[9] Lin JC, Wu YY, Wu JY, et al. TROP2 is epigenetically inactivated and modulates IGF-1R signalling in lung adenocarcinoma[J]. EMBO Mol Med, 2012, 4(6):472-485.
[10] Cubas R, Li M, Chen C, et al. Trop2: a possible therapeutic target for late stage epithelial carcinomas[J]. Biochim Biophys Acta, 2009, 1796(2):309-314.
[11] Guerra E, Lattanzio R, La Sorda R, et al. mTrop1/Epcam knockout mice develop congenital tufting enteropathy through dysregulation of intestinal E-cadherin/β-catenin[J]. PLoS One, 2012, 7(11):e49302.
[12] McDougall AR, Hooper SB, Zahra VA, et al. The oncogene Trop2 regulates fetal lung cell proliferation[J]. Am J Physiol Lung Cell Mol Physiol, 2011, 301(4):L478-L489.
[13] Xie J, Mølck C, Paquet-Fifield S, et al. High expression of TROP2 characterizes different cell subpopulations in androgen-sensitive and androgen-independent prostate cancer cells[J]. Oncotarget, 2016, 7(28):44492-44504.
[14] Guan H, Guo Z, Liang W, et al. Trop2 enhances invasion of thyroid cancer by inducing MMP2 through ERK and JNK pathways[J]. BMC Cancer, 2017, 17(1):486.
[15] Liu T, Liu Y, Bao X, et al. Overexpression of TROP2 predicts poor prognosis of patients with cervical cancer and promotes the proliferation and invasion of cervical cancer cells by regulating ERK signaling pathway[J]. PloS One, 2013, 8(9):e75864.
[16] Vermeulen K, van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer[J]. Cell Prolif, 2003, 36(3):131-149.
[17] 葛亚楠, 朱欢欢, 韩涛, 等. 细胞周期蛋白在三阴型和激素依赖型乳腺癌中的差异表达及临床意义[J]. 解放军医药杂志, 2016, 28(6):27-32.
[18] 张影. 抗Cyclin D1胞内抗体对三阴性乳腺癌生长和转移的抑制作用及机制研究[D]. 吉林: 吉林大学, 2020.
[19] Guerra E, Trerotola M, Aloisi AL, et al. The Trop-2 signalling network in cancer growth[J]. Oncogene, 2013, 32(12):1594-1600.
[20] Zhao W, Kuai X, Zhou X, et al. Trop2 is a potential biomarker for the promotion of EMT in human breast cancer[J]. Oncol Rep, 2018, 40(2):759-766.
[21] Tsai JH, Yang J. Epithelial-mesenchymal plasticity in carcinoma metastasis[J]. Genes Dev, 2013, 27(20):2192-2206.
[22] Sahota S, Vahdat LT. Sacituzumab govitecan: an antibody-drug conjugate[J]. Expert Opin Biol Ther, 2017, 17(8):1027-1031.
[23] Starodub AN, Ocean AJ, Shah MA, et al. First-in-human trial of a novel anti-Trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors[J]. Clin Cancer Res, 2015, 21(17):3870-3878.
[24] Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer[J]. N Engl J Med, 2019, 380(8):741-751.
[25] Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer[J]. N Engl J Med, 2021, 384(16):1529-1541.
[26] van Rij CM, Lütje S, Frielink C, et al. Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody[J]. Eur J Nucl Med Mol Imaging, 2013, 40(9):1377-1383.
[27] Updated clinical results and new biomarker analyses presented for Daiichi Sankyo′s DS-1062 in patients with advanced NSCLC at 2019 World Conference on Lung Cancer[EB/OL]. [2019-09-10]. .
[28] 李群. SKB264在局部晚期或转移实体瘤患者中的开放、国际多中心Ⅰ-Ⅱ期首次人体试验(FIH)的初步结果[EB/OL]. [2021-04-27]. .
Options
文章导航

/

〈 〉